Aligos Therapeutics, Inc. (ALGS) Stock Price & Analysis
Aligos Therapeutics, Inc. (ALGS) rose 3.63% to USD 5.14 as of June 10, 2026 at 07:32 UTC, according to Nexqual real-time market data.
ALGS last closed at USD 4.96; the session ranged USD 4.99–5.29 on volume of 81,099 shares. Market capitalization is $31.81M, with a 52-week range of USD 4.8–13.69 (NCM). Source: Nexqual, June 10, 2026 at 07:32 UTC.
Key Statistics (as of June 10, 2026 at 07:32 UTC)
| Price | USD 5.14 |
|---|---|
| Change | ▲ 3.63% (up) |
| Previous Close | USD 4.96 |
| Open | USD 5.05 |
| Day Range | USD 4.99 – 5.29 |
| 52-Week Range | USD 4.8 – 13.69 |
| Volume | 81,099 shares |
| Market Cap | $31.81M |
| Exchange | NCM |
Technical Analysis (ALGS)
Nexqual's technical model rates ALGS "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:32 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.3 (neutral) |
| vs SMA50 | Below (USD 6.46) |
| MACD | -0.37 (negative) |
Analyst Ratings (ALGS)
Wall Street analysts rate ALGS "Strong Buy" based on 7 analysts, with a mean price target of USD 56.29 (range USD 20–175), per Nexqual as of June 10, 2026 at 07:32 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 56.29 |
| High Target | USD 175 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (ALGS)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -1.25 |
| Revenue Estimate | $17.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -2.21 vs est -2.37 ▲ beat |
| 2025-12-31 | USD -1.91 vs est -2.49 ▲ beat |
| 2025-09-30 | USD -3.04 vs est -2.01 ▼ miss |
| 2025-06-30 | USD -1.53 vs est -2.54 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financials & Fundamentals (ALGS)
| Total Revenue | $4.71M |
|---|---|
| Revenue Growth (YoY) | +810.00% |
| Gross Margin | +0.00% |
| Operating Margin | -951.55% |
| Profit Margin | +0.00% |
| ROE | -121.86% |
| Debt / Equity | 13.69 |
| Current Ratio | 2.56 |
| Total Cash | $54.91M |
| Total Debt | $4.35M |
| Free Cash Flow | $-49.34M |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financial Health Score (ALGS)
Nexqual rates Aligos Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:32 UTC.
| Growth | Critical — Revenue -45% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $55M cash vs $4M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$49M, burning cash |
| Efficiency | Critical — ROE -122%, ROA -55.6% |
Ownership (ALGS)
| Insider Ownership | +10.37% |
|---|---|
| Institutional Ownership | +55.08% |
| Shares Outstanding | 5.39M |
| Float | 3.64M |
| Short % of Float | +10.99% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Leadership (ALGS)
Aligos Therapeutics, Inc. is led by Lawrence M. Blatt (age 63), CEO, President & Chairman of the Board, per Nexqual as of June 10, 2026 at 07:32 UTC.
| CEO, President & Chairman of the Board | Lawrence M. Blatt (age 63) |
|---|---|
| Executive VP & Chief Scientific Officer | Julian A. Symons DPHIL (age 63) |
| Executive Vice President & Chief Development Officer | Sushmita M. Chanda DABT (age 58) |
| Vice President & Head of Chemistry Manufacturing Controls | Kieron Wesson |
Major Backers & Investors (ALGS)
Notable institutional backers of Aligos Therapeutics, Inc. include Deep Track Capital, Lp, Alyeska Investment Group, L.p., Sio Capital Management, LLC, according to Nexqual as of June 10, 2026 at 07:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deep Track Capital, Lp | 8.24% |
| Alyeska Investment Group, L.p. | 7.65% |
| Sio Capital Management, LLC | 6.07% |
| Marshall Wace LLP | 4.96% |
| Bank of America Corporation | 4.26% |
| Woodline Partners LP | 3.29% |
| Summittx Capital, L.P. | 2.76% |
| Renaissance Technologies | 1.86% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.62% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
From Aligos Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases.
- Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
- The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus.
- The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANNX | Annexon, Inc. | USD 5.2 | ▼ 1.7% |
| PMVP | PMV Pharmaceuticals, Inc. | USD 1.05 | ▼ 6.25% |
| ALXO | ALX Oncology Holdings Inc. | USD 1.55 | ▲ 0.65% |
| FHTX | Foghorn Therapeutics Inc. | USD 3.87 | ▲ 3.75% |
| PASG | Passage Bio, Inc. | USD 5.57 | ▼ 0.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:32 UTC. This page is informational and not investment advice.